Mark Schabbing
Family Medicine · Perryville, MONPI 1861584534
Payments from drug & device makers
Across 457 payments — averaging $19.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$5K
- Lilly USA, LLC$666
- Novo Nordisk$442
- Novartis$438
- Amgen$324
- Boehringer Ingelheim$276
- plus $2K from 27 others
What the payments were for
- Food & beverage$8,728100%
- Education$350%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 207 | $4,535 |
| Lilly USA, LLC | 39 | $666 |
| Novo Nordisk | 24 | $442 |
| Novartis | 26 | $438 |
| Amgen | 20 | $324 |
| Boehringer Ingelheim | 18 | $276 |
| AstraZeneca | 9 | $232 |
| Bayer | 11 | $205 |
| Johnson & Johnson | 13 | $189 |
| Otsuka America Pharmaceutical, Inc. | 9 | $171 |
| Merck | 10 | $168 |
| GSK | 11 | $157 |
| Biohaven Pharmaceutical Holding Company Ltd. | 7 | $124 |
| Exact Sciences | 4 | $85 |
| Astellas Pharma US Inc | 5 | $78 |
| Sunovion Pharmaceuticals Inc. | 5 | $76 |
| Sumitomo Pharma America, Inc. | 6 | $74 |
| Amarin Pharma, Inc. | 4 | $70 |
| Abbott | 4 | $61 |
| Pfizer | 4 | $60 |
| Phathom Pharmaceuticals, Inc. | 4 | $59 |
| Medtronic | 3 | $58 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Dexcom, Inc. | 2 | $33 |
| Eisai Inc. | 2 | $32 |
| Lundbeck LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Alkermes, Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Supernus Pharmaceuticals, Inc. | 1 | $12 |
| Mylan Specialty L.p. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,763 in reported general payments places this provider in the 90th percentile of 2,203 family medicine providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 147 | $171,889 |
| EliquisApixaban | 234 | $159,313 |
| FarxigaDapagliflozin Propanediol | 115 | $99,344 |
| OzempicSemaglutide | 67 | $84,627 |
| XareltoRivaroxaban | 64 | $46,511 |
| TrulicityDulaglutide | 36 | $46,188 |
| MounjaroTirzepatide | 39 | $38,221 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $38,215 |
| MyrbetriqMirabegron | 47 | $29,479 |
| LinzessLinaclotide | 49 | $27,145 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 87 | $25,689 |
| GemtesaVibegron | 28 | $20,137 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 34 | $19,471 |
| EntrestoSacubitril/Valsartan | 12 | $19,173 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $18,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $276 | $190,429171 claims |
| PfizerEliquis | $60 | $159,313234 claims |
| AstraZenecaFarxiga | $232 | $99,344115 claims |
| Novo NordiskOzempic, Xultophy 100-3.6 | $442 | $98,64878 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $666 | $84,40975 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy | $157 | $75,921133 claims |
| Johnson & JohnsonXarelto | $189 | $46,51164 claims |
| Astellas Pharma US IncMyrbetriq | $78 | $29,47947 claims |
| AbbVieLinzess | $4,535 | $27,14549 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $74 | $20,13728 claims |
| NovartisEntresto | $438 | $19,17312 claims |
| BayerKerendia | $205 | $16,96118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Perryville
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.